Metrics & Benchmarks

>

Latest News

Genmab’s Epkinly Shows Major Survival Benefit in Relapsed, Refractory Follicular Lymphoma
Genmab’s Epkinly Shows Major Survival Benefit in Relapsed, Refractory Follicular Lymphoma

August 8th 2025

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or refractory follicular lymphoma demonstrated significant improvements in overall response rate and progression-free survival.

Eli Lilly’s Investigational Oral GLP-1 Receptor Agonist Demonstrates Significant Weight Loss
Eli Lilly’s Investigational Oral GLP-1 Receptor Agonist Demonstrates Significant Weight Loss

August 7th 2025

MetaVia Expands GLP-1 Glucagon Receptor Agonist Obesity Trial Amid Signs of Superior Tolerability
MetaVia Expands GLP-1 Glucagon Receptor Agonist Obesity Trial Amid Signs of Superior Tolerability

August 6th 2025

Vertex’s Selective NaV1.8 Inhibitor Falls Short in Acute Pain Clinical Trial
Vertex’s Selective NaV1.8 Inhibitor Falls Short in Acute Pain Clinical Trial

August 5th 2025

FDA Clears Alphamab’s Anti-HER2 Biparatopic Antibody-Drug Conjugate for Phase II Ovarian Cancer Trial
FDA Clears Alphamab’s Anti-HER2 Biparatopic Antibody-Drug Conjugate for Phase II Ovarian Cancer Trial

August 1st 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.